28th March 2025
Here is a roundup of our top biotech and pharma industry insights for Q1 2025.
Biotech news round up for Q1
AstraZeneca has announced its acquisition of Belgium-based Esobiotec for up to $1 billion. Esobiotec specializes in innovative cell therapy technology that significantly reduces treatment times by delivering therapeutic instructions directly to immune cells within the patient’s body, contrasting with traditional methods requiring external genetic modification of extracted cells. The acquisition includes an initial payment of $425 million, with up to $575 million in future milestone-based payments. Esobiotec’s lentiviral technology platform aims to reduce manufacturing complexities and costs, potentially increasing patient access to advanced cancer therapies. This move aligns with AstraZeneca’s ongoing focus on immune-based cancer treatments and adds to its pipeline of cell therapy capabilities. Read here
The UK’s National Health Service (NHS) has launched the Cancer Vaccine Launch Pad, a collaboration for trials using personalized mRNA cancer vaccines on its patients. These vaccines aim to target existing tumors by engineering an mRNA-mediated immune response tailored to the patient’s specific cancer cells. Experimental treatments are underway for various cancers, including pancreatic, head and neck, and melanoma. This initiative represents a significant advancement in cancer treatment, leveraging mRNA technology to develop personalized therapies. Read here
Abingworth, a UK-based life sciences investor backed by Carlyle, is raising a fund of up to $1.5 billion to support clinical trials through partnerships with major pharmaceutical firms. The fund aims to finance approximately eight late-stage trials and expects to return $500 million to investors amid a challenging biotech venture capital environment. Recent deals include collaborations with Gilead Sciences and Teva, focusing on developing treatments for lung cancer and asthma. Abingworth boasts a high success rate, with about 80% of financed experimental medicines obtaining approvals, compared to the industry average of 55-60%. Read here
BioNTech, a German biotechnology company, is expanding its oncology pipeline and drug manufacturing capabilities. The company has formed strategic collaborations and acquisitions to enhance its platform technologies, including the acquisition of InstaDeep, a British AI technology company, to strengthen its AI-driven approach in drug development. BioNTech’s initiatives aim to advance personalized mRNA cancer immunotherapies and increase global manufacturing capacity, with projects such as the BioNTainer system for decentralized production of mRNA-based medicines. Read here
